JNJ
NEUTRAL
$237.96
Live
Johnson & Johnson · NYSE
Target $241.92
(+1.7%)
$146.12
52W Range
$251.71
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 14, 2026
Market cap
$573.46B
P/E
21.55
ROE
35.0%
Profit margin
28.5%
Debt/Equity
0.6
Dividend yield
2.19%
AI Analysis
AI-powered fundamental assessment
Confidence
85%
JNJ presents a dichotomy between strong profitability and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the company maintains an impressive ROE of 35.03% and a consistent history of earnings beats, the current price of $237.96 trades at a significant premium to its Graham Number of $91.72. Growth remains robust on a YoY basis, but bearish insider sentiment and a very weak technical trend (10/100) suggest immediate headwinds. The stock is fundamentally sound in terms of earnings power but shows signs of operational inefficiency or declining quality in its deterministic health metrics.
Key Strengths
Exceptional Return on Equity (ROE) of 35.03%
Strong profit margins (28.46%) and gross margins (68.08%)
Consistent earnings beat track record over 25 quarters
Sustainable dividend payout ratio of 46.60%
Strong YoY earnings growth of 48.60%
Key Risks
Weak Piotroski F-Score (3/9) indicating declining fundamental health
Bearish insider activity with $58.35M in net sales and zero buys
Low liquidity indicated by a Quick Ratio of 0.69
Significant divergence between current price and Graham defensive value
Negative most recent Q/Q EPS growth (-12.1%)
AI Fair Value Estimate
Based on comprehensive analysis
$245.5
+3.2% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
60
Strong
45
70
90
30
65
AI Verdict
Hold
Key drivers: High profitability, Weak deterministic health score, Bearish technicals/insiders, Strong historical earnings consistency
Confidence
90%
Value
45/100
Trades at a premium to defensive value but below growth-based intrinsic value ($325.68).
Positives
- Forward P/E (18.90) is reasonable for the sector
Watchpoints
- Price is 158% above Graham Number
- High Price/Book (7.03)
Future
70/100
Growth is strong annually but showing signs of short-term volatility.
Positives
- Strong YoY Revenue (9.1%) and Earnings (48.6%) growth
Watchpoints
- Recent Q/Q EPS contraction of 12.1%
Past
90/100
Historically one of the most reliable earnings performers in healthcare.
Positives
- 25-quarter track record of meeting or beating estimates
- Strong 5-year price appreciation (+71.3%)
Watchpoints
No urgent risks highlighted.
Health
30/100
Deterministic health metrics are the primary area of concern.
Positives
- Manageable Debt/Equity ratio (0.60)
Watchpoints
- Piotroski F-Score of 3/9 is in the 'Weak' category
- Quick Ratio (0.69) suggests potential short-term liquidity pressure
Dividend
65/100
Safe and sustainable, though not high-yield.
Positives
- Sustainable payout ratio (46.6%)
- Consistent dividend rate
Watchpoints
- Yield (2.19%) is moderate and not a primary driver for total return
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$237.96
Analyst Target
$241.92
Upside/Downside
+1.7%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for JNJ and closest competitors.
Updated 2026-04-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
JNJ
Johnson & Johnson
Primary
|
+71.3% | +56.9% | +58.5% | +26.1% | -1.5% | -1.2% |
|
ABBV
AbbVie Inc.
Peer
|
+140.3% | +65.5% | +32.8% | +17.0% | -3.9% | +2.3% |
|
MRK
Merck & Co., Inc.
Peer
|
+93.0% | +22.1% | +44.3% | +36.7% | +0.6% | +1.6% |
|
UNH
UnitedHealth Group Incorporated
Peer
|
-11.6% | -29.1% | -21.8% | -10.0% | +17.4% | +3.4% |
|
LLY
Eli Lilly and Company
Peer
|
+444.3% | +179.6% | +20.0% | +16.6% | -5.8% | +4.7% |
JNJ
Johnson & Johnson
Primary
5Y
+71.3%
3Y
+56.9%
1Y
+58.5%
6M
+26.1%
1M
-1.5%
1W
-1.2%
ABB
AbbVie Inc.
Peer
5Y
+140.3%
3Y
+65.5%
1Y
+32.8%
6M
+17.0%
1M
-3.9%
1W
+2.3%
MRK
Merck & Co., Inc.
Peer
5Y
+93.0%
3Y
+22.1%
1Y
+44.3%
6M
+36.7%
1M
+0.6%
1W
+1.6%
UNH
UnitedHealth Group Incorporated
Peer
5Y
-11.6%
3Y
-29.1%
1Y
-21.8%
6M
-10.0%
1M
+17.4%
1W
+3.4%
LLY
Eli Lilly and Company
Peer
5Y
+444.3%
3Y
+179.6%
1Y
+20.0%
6M
+16.6%
1M
-5.8%
1W
+4.7%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
21.55
Forward P/E
18.9
PEG Ratio
1.67
P/B Ratio
7.03
P/S Ratio
6.09
EV/Revenue
6.4
EV/EBITDA
17.81
Market Cap
$573.46B
Profitability
Profit margins and return metrics
Profit Margin
28.46%
Operating Margin
23.97%
Gross Margin
68.08%
ROE
35.03%
ROA
8.68%
Growth
Revenue and earnings growth rates
Revenue Growth
+9.1%
Earnings Growth
+48.6%
Q/Q Revenue Growth
+9.08%
Q/Q Earnings Growth
+49.1%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.6
Moderate
Current Ratio
1.03
Good
Quick Ratio
0.69
Poor
Cash/Share
$8.34
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$24.6B
Gross Margin
67.6%
Op. Margin
22.8%
Net Margin
20.8%
Total Assets
$199.2B
Liabilities
$117.7B
Equity
$81.5B
Debt/Equity
1.44x
Operating CF
$7.3B
CapEx
$-1.8B
Free Cash Flow
$5.5B
FCF Yield
75%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-04-14
$N/A
2026-01-21
$2.46
-0.1% surprise
2025-10-14
$2.8
+1.5% surprise
2025-07-16
$2.77
+3.2% surprise
Healthcare Sector Comparison
Comparing JNJ against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
P/E Ratio
21.55
This Stock
vs
75.44
Sector Avg
-71.4%
(Discount)
Return on Equity (ROE)
35.03%
This Stock
vs
-88.14%
Sector Avg
-139.7%
(Below Avg)
Profit Margin
28.46%
This Stock
vs
-16.28%
Sector Avg
-274.8%
(Weaker)
Debt to Equity
0.6
This Stock
vs
2.66
Sector Avg
-77.3%
(Less Debt)
Revenue Growth
9.1%
This Stock
vs
124.04%
Sector Avg
-92.7%
(Slower)
Current Ratio
1.03
This Stock
vs
4.47
Sector Avg
-77.0%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
JNJ
Johnson & Johnson
|
NEUTRAL | $573.46B | 21.55 | 35.0% | 28.5% | $237.96 | |
|
ABBV
AbbVie Inc.
|
NEUTRAL | $387.52B | 163.63 | 138.0% | 4.0% | $219.26 | Compare |
|
MRK
Merck & Co., Inc.
|
NEUTRAL | $299.79B | 16.66 | 36.9% | 28.1% | $121.25 | Compare |
|
UNH
UnitedHealth Group Incorporated
|
NEUTRAL | $293.61B | 24.43 | 12.5% | 2.7% | $323.48 | Compare |
|
LLY
Eli Lilly and Company
|
NEUTRAL | $858.01B | 41.7 | 101.2% | 31.7% | $958.65 | Compare |
JNJ
Johnson & Johnson
NEUTRAL
Mkt Cap
$573.5B
P/E
21.6
ROE
35.0%
Price
$237.96
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-27 | DECKER ROBERT J | Officer | Option Exercise | 4,075 | $471,355 |
| 2026-02-27 | DECKER ROBERT J | Officer | Sale | 4,075 | $1,010,070 |
| 2026-02-20 | SCHMID TIMOTHY | Officer | Sale | 1,322 | $324,763 |
| 2026-02-18 | SCHMID TIMOTHY | Officer | Sale | 22,623 | $5,527,506 |
| 2026-02-18 | SCHMID TIMOTHY | Officer | Option Exercise | 29,554 | $2,741,335 |
| 2026-02-17 | SWANSON JAMES D | Chief Technology Officer | Sale | 62,080 | $15,109,759 |
| 2026-02-17 | SWANSON JAMES D | Chief Technology Officer | Option Exercise | 73,140 | $10,202,710 |
| 2026-02-17 | BROADHURST VANESSA | Officer | Sale | 6,197 | $1,508,288 |
| 2026-02-17 | WOLK JOSEPH J | Chief Financial Officer | Sale | 89,654 | $21,767,827 |
| 2026-02-17 | WOLK JOSEPH J | Chief Financial Officer | Option Exercise | 107,784 | $8,193,223 |
| 2026-02-17 | REED JOHN C | Officer | Sale | 53,931 | $13,105,233 |
| 2026-02-17 | REED JOHN C | Officer | Option Exercise | 54,844 | $8,103,281 |
| 2026-02-13 | BROADHURST VANESSA | Officer | Stock Award | 10,020 | - |
| 2026-02-13 | FORMINARD ELIZABETH | Officer | Stock Award | 16,381 | - |
| 2026-02-13 | MULHOLLAND KRISTEN | Officer | Stock Award | 5,006 | - |
DECKER ROBERT J
Officer
2026-02-27
4,075 shares
·
$471,355
DECKER ROBERT J
Officer
2026-02-27
4,075 shares
·
$1,010,070
SCHMID TIMOTHY
Officer
2026-02-20
1,322 shares
·
$324,763
SCHMID TIMOTHY
Officer
2026-02-18
22,623 shares
·
$5,527,506
SCHMID TIMOTHY
Officer
2026-02-18
29,554 shares
·
$2,741,335
SWANSON JAMES D
Chief Technology Officer
2026-02-17
62,080 shares
·
$15,109,759
SWANSON JAMES D
Chief Technology Officer
2026-02-17
73,140 shares
·
$10,202,710
BROADHURST VANESSA
Officer
2026-02-17
6,197 shares
·
$1,508,288
WOLK JOSEPH J
Chief Financial Officer
2026-02-17
89,654 shares
·
$21,767,827
WOLK JOSEPH J
Chief Financial Officer
2026-02-17
107,784 shares
·
$8,193,223
REED JOHN C
Officer
2026-02-17
53,931 shares
·
$13,105,233
REED JOHN C
Officer
2026-02-17
54,844 shares
·
$8,103,281
BROADHURST VANESSA
Officer
2026-02-13
10,020 shares
FORMINARD ELIZABETH
Officer
2026-02-13
16,381 shares
MULHOLLAND KRISTEN
Officer
2026-02-13
5,006 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
24 analysts
Morgan Stanley
2026-04-10
Overweight
Overweight
RBC Capital
2026-03-30
Outperform
Outperform
Barclays
2026-03-19
Equal-Weight
Equal-Weight
HSBC
2026-03-17
Buy
Buy
Citigroup
2026-03-11
Buy
Buy
JP Morgan
2026-03-05
Neutral
Neutral
RBC Capital
2026-02-03
Outperform
Outperform
Morgan Stanley
2026-01-28
Equal-Weight
Overweight
Freedom Capital Markets
2026-01-27
Hold
Hold
Freedom Broker
2026-01-27
Hold
Hold
Past News Coverage
Recent headlines mentioning JNJ from our newsroom.
Newest → oldest
No matching news yet.